Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $31.4 million.

  • UroGen Pharma's Cash from Investing Activities rose 129.41% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 202.04%. This contributed to the annual value of -$20.6 million for FY2024, which is 2062.96% down from last year.
  • As of Q3 2025, UroGen Pharma's Cash from Investing Activities stood at $31.4 million, which was up 10.53% from $28.4 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Cash from Investing Activities peaked at $60.6 million during Q4 2024, and registered a low of -$106.8 million during Q3 2024.
  • Its 3-year average for Cash from Investing Activities is $1.1 million, with a median of $6.3 million in 2023.
  • Per our database at Business Quant, UroGen Pharma's Cash from Investing Activities skyrocketed by 2,563.58% in 2023 and then slumped by 26,720.95% in 2024.
  • Over the past 5 years, UroGen Pharma's Cash from Investing Activities (Quarterly) stood at $9.1 million in 2021, then soared by 153.24% to $23.1 million in 2022, then tumbled by 149.09% to -$11.3 million in 2023, then surged by 634.39% to $60.6 million in 2024, then skyrocketed by 129.41% to $31.4 million in 2025.
  • Its Cash from Investing Activities was $31.4 million in Q3 2025, compared to $28.4 million in Q2 2025 and -$26.0 million in Q1 2025.